Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of a poster entitled Cellular and Molecular Impact of the Melanocortin Receptor Agonist PL8177 in DSS Induced Colitis in Rats at the United European Gastroenterology Week (UEG) being held October 14-17 2023 in Copenhagen, Denmark. Lead author Paul S. Kayne, Ph.D., Vice P